GHRP-6

GHRP-6's defining action is its ability to trigger growth hormone secretion from the pituitary. Laboratory work in pituitary cell cultures has shown that the peptide stimulates GH release in both time- and dose-dependent fashion, and it amplifies the GH response when given alongside GHRH (3). The mechanism involves activation of protein kinase C — specifically the PKCσ isoform — which in turn phosphorylates CREB, a transcription factor that switches on genes involved in growth hormone production. Knockdown experiments confirmed that without PKCσ, the GHRP-6 signal largely fails to propagate, pinpointing this kinase as a key relay in the pathway (3).

Clinically, GHRP-6 has been used as a diagnostic probe of pituitary GH reserve. Studies in short-statured children and adults with growth hormone deficiency found that GH responses to intravenous GHRP-6 were reproducibly lower than in unaffected individuals, and the combined GHRH plus GHRP-6 test proved especially useful for identifying adult-onset GH deficiency and pituitary stalk transection (5, 6). One observation that emerged from this work: GHRP-6's response is more reproducible than GHRH's across repeated testing, and the two secretagogues appear to provide complementary information about how the GH axis is functioning (6).

Beyond its endocrine role, GHRP-6 has been investigated as a cardioprotective agent. A 2024 study examined whether GHRP-6 could prevent the cardiac damage caused by doxorubicin, a widely used chemotherapy drug notorious for producing dilated cardiomyopathy and heart failure (2). When GHRP-6 was given alongside doxorubicin, treated subjects showed preserved left ventricular systolic function, no ventricular dilation, and reduced damage to other organs — outcomes that translated into lower overall mortality.

The mechanism appears to center on cellular survival. GHRP-6 sustained antioxidant defenses, upregulated Bcl-2 (a gene that protects cells from programmed death), and preserved the structural integrity of mitochondria — the energy-producing compartments inside heart cells that doxorubicin tends to destroy (2). These findings suggest GHRP-6 may act as a broad pro-survival signal at the cellular level, with implications that extend beyond the heart to any tissue facing oxidative or chemotherapeutic stress.

A 2025 study took GHRP-6 in a different direction by formulating it as a self-assembling hydrogel — a gel that forms spontaneously from peptide building blocks — and testing it in acute kidney injury (1). Renal tubular epithelial cells, which line the kidney's filtering tubules, are highly vulnerable during acute injury but also drive recovery if they survive. The GHRP-6 hydrogel appeared to reprogram the metabolism of these cells, helping them survive ischemic conditions where blood and oxygen supply are limited.

Metabolomic analysis showed that treated kidneys were enriched in spermidine, L-glutamine, and acetyl-CoA — molecules tied to amino acid and fatty acid metabolism that support cell survival and regeneration (1). Mechanistically, the hydrogel activated the mTOR-P70 pathway, a master regulator of cell growth and protein synthesis. This metabolic reprogramming angle is novel for GHRP-6 and suggests the peptide may have applications in regenerative medicine that go well beyond growth hormone release.

An interesting and less-discussed property of GHRP-6 is its ability to stimulate the hypothalamic-pituitary-adrenal axis — the system that produces cortisol. A clinical study in patients with Cushing's disease (a condition driven by ACTH-secreting pituitary tumors) showed that intravenous GHRP-6 produced significant increases in both ACTH and cortisol, with response magnitudes comparable to those produced by DDAVP, a vasopressin analog (4). The peak cortisol responses to the two compounds correlated tightly, suggesting overlapping mechanisms — possibly involving vasopressin signaling at the level of the corticotroph adenoma.

This effect is worth knowing about because it means GHRP-6's pharmacology isn't limited to the GH axis. Users and researchers should be aware that the peptide can transiently elevate cortisol, particularly at the doses used in diagnostic testing, which may be relevant for those tracking stress hormones or interpreting endocrine test results.

Reported side effects of GHRP-6 in published research are generally mild. The most consistently noted effect is an increase in appetite, since GHRP-6 acts at the ghrelin receptor — the same receptor that drives hunger signaling. Transient elevations in cortisol and prolactin have been documented at higher doses, particularly in diagnostic testing contexts (4). Users sometimes report mild fatigue or flushing after injection, which typically resolves quickly.

The body of GHRP-6 evidence comes primarily from preclinical and laboratory work alongside a smaller set of clinical diagnostic studies, with limited long-term human data. Because GHRP-6 stimulates the GH axis, it falls within categories of compounds restricted by the World Anti-Doping Agency for competitive athletes — relevant context for anyone subject to sports testing.